CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS([*]), HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE EXCHANGE ACT OF 1934, AS AMENDED RESEARCH,...Research, Development and Commercialization Agreement • June 5th, 2006 • Combinatorx, Inc • Pharmaceutical preparations • Maryland
THIS RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT is made this day of May, 2006, (the “Effective Date”) (the “Agreement”), by and between CombinatoRx, Incorporated (“CombinatoRx”), a Delaware corporation with principal offices at 245 First Street, Cambridge, MA, 02142 (“CombinatoRx”), and Cystic Fibrosis Foundation Therapeutics Incorporated, a Maryland corporation with principal offices at 6931 Arlington Road, Bethesda, Maryland 20814 (“CFFT”). CombinatoRx and CFFT may each be referred to as a “party” and collectively, as the “Parties.”
